SUVEN Life Sciences Ltd

Suven Life Sciences presented Pre-clinical data of their NCEs at Society for Neuroscience (SFN) Annual Meeting, Washington DC, USA

HYDERABAD, INDIA (November 21, 2005) – Several data presentations from Suven's portfolio of investigational neuroscience compounds were presented at last week's Neuroscience 2005 meeting held at Washington D.C, USA. Neuroscience is the annual meeting of the **Society for Neuroscience** (**SFN**).

Suven has presented new data for 4 promising areas of neuroscience viz. Alzheimer's, Schizophrenia, Parkinson and Obesity diseases. These areas present significant unmet medical need for which current treatment options are insufficient. Suven has a number of programs in each of these areas, focusing on novel approaches that may lead to the development of new therapies for patients.

Following are Suven's presentations at SFN:

• Effect of selective 5-HT6 receptor antagonists on food-intake and body weight gain. • SUVN-501: A potent and selective 5-HT6-receptor antagonist reverses scopolamine-induced amnesia in Morris water maze. • SUVN-502: Pharmacological profile of SUVN-502: A potent and selective 5-HT6-receptor antagonist. • Effect of selective 5-HT6 receptor antagonists SUVN-501 and SUVN-502 in rodent model of working memory. • Effect of selective 5-HT6 receptor antagonists in rodent models of learning

Suven is committed to neuroscience research and for development of new treatments for neurological disorders. Suven's discovery research focuses on Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches. Suven's CNS drug discovery scientists at Hyderabad , India are pursuing innovative ways to develop treatments for a variety of CNS disorders like Alzheimer's, Schizophrenia, Depression, Cognitive disorders and Neurodegeneration.

Suven Life Sciences, a Hyderabad based Life Sciences Company, pioneer in Contract Research And Manufacturing Services (CRAMS) since 1995 in its endeavor to become collaborative research partner (CRP) for global life science companies has embarked on new business model " Drug Discovery and Development Support Services " (DDDSS) with the onset of Intellectual Property Regime in India since January 2005.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 170 professionals with the state of the art infrastructure for Drug Discovery and development activities with 30 clinical research professionals and the front-end project management services from New Jersey , USA . For more information on Suven, please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;